Next Article in Journal / Special Issue
Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis
Previous Article in Journal
Why do We Find It so Hard to Discuss Spirituality? A Qualitative Exploration of Attitudinal Barriers
Previous Article in Special Issue
Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2016, 5(9), 78; doi:10.3390/jcm5090078

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis

1
North West Interstitial Lung Disease Unit, University Hospital of South Manchester, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M29 9LT, UK
2
Manchester Academic Health Science Centre, The University of Manchester, Oxford Road, Manchester M13 9PL, UK
3
Manchester Medical School, The University of Manchester, Oxford Road, Manchester M13 9PL, UK
*
Author to whom correspondence should be addressed.
Academic Editor: David Barnes
Received: 24 July 2016 / Revised: 24 August 2016 / Accepted: 30 August 2016 / Published: 2 September 2016
(This article belongs to the Special Issue Chronic Respiratory Diseases)
View Full-Text   |   Download PDF [1654 KB, uploaded 2 September 2016]   |  

Abstract

Idiopathic Pulmonary Fibrosis (IPF) now has two licensed treatments available. Pirfenidone was the first drug to be licensed and approved for use, followed by nintedanib. We set out our real world experience with these agents in terms of their adverse events profile outside the restrictions of a clinical trial. We have demonstrated in the real world setting, that side effects are common and predominantly gastrointestinal with both therapies. Our study shows that the side effects can be effectively managed in the majority of patients with an acceptable discontinuation rate similar to that seen in the clinical trials. These findings are compelling despite the fact that the patients in our study are older, have severer disease as depicted by baseline lung function and more co-morbidities. Our data provides ongoing evidence of the safety and tolerability of both pirfenidone and nintedanib in patients who would not have met the rigorous criteria to be included in a clinical trial. Both these agents are effective in the management of IPF and slow the progression of this debilitating life limiting condition. View Full-Text
Keywords: pirfenidone; nintedanib; IPF; Idiopathic Pulmonary Fibrosis pirfenidone; nintedanib; IPF; Idiopathic Pulmonary Fibrosis
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hughes, G.; Toellner, H.; Morris, H.; Leonard, C.; Chaudhuri, N. Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J. Clin. Med. 2016, 5, 78.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top